Cinetose

Referências

Principais artigos

Centers for Disease Control and Prevention. CDC health information for international travel (Yellow Book): motion sickness. Jun 2019 [internet publication].Texto completo

Spinks AB, Wasiak J. Scopolamine (hyoscine) for preventing and treating motion sickness. Cochrane Database Syst Rev. 2011;(6):CD002851.Texto completo  Resumo

Artigos de referência

1. Stern RM, Koch KL, Andrews P. Nausea of motion sickness. In: Stern RM, Koch KL, Andrews P. Nausea: mechanisms and management. New York, NY: Oxford Press; 2011:331-353.

2. Benson AJ, Stott JR. Motion sickness. In: Rainford DJ, Gradwell DP. Ernsting's aviation medicine. 4th ed. London, UK: Hodder Arnold, Hodder Education; 2006:459-475.

3. Hu S, Grant WF, Stern RM, et al. Motion sickness severity and physiological correlates during repeated exposures to a rotating optokinetic drum. Aviat Space Environ Med. 1991;62:308-314. Resumo

4. Guerraz M, Yardley L, Bertholon P, et al. Visual vertigo: symptom assessment, spatial orientation and postural control. Brain. 2001;124:1646-1656.Texto completo  Resumo

5. Stanney KM, Hale KS, Nahmens I, et al. What to expect from immersive virtual environment exposure: influences of gender, body mass index, and past experience. Hum Factors. 2003;45:504-520. Resumo

6. Kennedy RS, Fowlkes JE. Simulator sickness is polygenic and polysymptomatic: implications for research. Int J Aviat Psychol. 1992;2:23-38.

7. Kennedy R, Lane N, Lilienthal M, et al. Profile analysis of simulator sickness symptoms: application to virtual reality environments. Presence. 1992;1:295-301.

8. Golding JF, Stott JR. Effect of sickness severity on habituation to repeated motion challenges in aircrew referred for airsickness treatment. Aviat Space Environ Med. 1995;66:625-630. Resumo

9. Centers for Disease Control and Prevention. CDC health information for international travel (Yellow Book): motion sickness. Jun 2019 [internet publication].Texto completo

10. Turner M, Griffin MJ. Motion sickness in public road transport: passenger behavior and susceptibility. Ergonomics. 1999;42:444-461. Resumo

11. Flanagan MB, May JG, Dobie TG. Sex differences in tolerance to visually-induced motion sickness. Aviat Space Environ Med. 2005;76:642-46. Resumo

12. Kennedy RS, Lanham DS, Massey CJ, et al. Gender differences in simulator sickness incidence: implications for military virtual reality systems. Safe J. 1995;25:69-76.

13. Klosterhalfen S, Kellermann S, Pan F, et al. Effects of ethnicity and gender on motion sickness susceptibility. Aviat Space Environ Med. 2005;76:1051-1057. Resumo

14. Lawther A, Griffin MJ. A survey of the occurrence of motion sickness amongst passengers at sea. Aviat Space Environ Med. 1988;59:399-406. Resumo

15. Stern RM, Hu S, LeBlanc R, et al. Chinese hyper-susceptibility to vection-induced motion sickness. Aviat Space Environ Med. 1993;64: 827-830. Resumo

16. Golding JF, Mueller AG, Gresty MA. A motion sickness maximum around the 0.2 Hz frequency range of horizontal translational oscillation. Aviat Space Environ Med. 2001;72:188-192. Resumo

17. Lawther A, Griffin MJ. Prediction of the incidence of motion sickness from the magnitude, frequency, and duration of vertical oscillation. J Acoust Soc Am. 1987;82:957-966. Resumo

18. O'Hanlon JF, McCauley ME. Motion sickness incidence as a function of the frequency and acceleration of vertical sinusoidal motion. Aerosp Med. 1974;45:366-369. Resumo

19. Kennedy RS, Drexler J, Kennedy RC. Research in visually induced motion sickness. Appl Ergon. 2010;41:494-503. Resumo

20. Bijveld MM, Bronstein AM, Golding JF, et al. Nauseogenicity of off-vertical axis rotation vs. equivalent visual motion. Aviat Space Environ Med. 2008;79:661-665. Resumo

21. Drummond PD. Triggers of motion sickness in migraine sufferers. Headache. 2005;45:653-656. Resumo

22. Stern RM, Koch KL, Stewart WR, et al. Spectral analysis of tachygastria recorded during motion sickness. Gastroenterol. 1987;92:92-97. Resumo

23. Neimer J, Eskiizmirliler S, Ventre-Dominey J, et al. Trains with a view to sickness. Curr Biol. 2001;11:R549-R550. Resumo

24. Williamson MJ, Thomas MJ, Stern RM. The contribution of expectations to motion sickness symptoms and gastric activity. Psychosom Res. 2004;56:721-726. Resumo

25. Houchens PW, Jones MB. Behavioral contagion in an experimental motion environment. Aviat Space Environ Med. 2003;74:649-653. Resumo

26. Zajonc TP, Roland PS. Vertigo and motion sickness. Part II: Pharmacologic treatment. Ear Nose Throat J. 2006;85:25-35. Resumo

27. Zajonc TP, Roland PS. Vertigo and motion sickness. Part I: vestibular anatomy and physiology. Ear Nose Throat J. 2005;84:581-584. Resumo

28. Ventre-Dominey J, Luyat M, Denise P, et al. Motion sickness induced by otolith stimulation is correlated with otolith-induced eye movements. Neuroscience. 2008;155:771-779. Resumo

29. Dai M, Kunin M, Raphan T, et al. The relation of motion sickness to the spatial-temporal properties of velocity storage. Exp Brain Res. 2003;151:173-189. Resumo

30. Cohen B, Dai M, Yakushin SB, et al. Baclofen, motion sickness susceptibility and the neural basis for velocity storage. Prog Brain Res. 2008;171:543-553. Resumo

31. Stern RM, Leibowitz HW, Unblad I, et al. Tachygastria and motion sickness. Aviat Space Environ Med. 1985;56:1074-1077. Resumo

32. Drummond PD. Effect of tryptophan depletion on symptoms of motion sickness in migraineurs. Neurology. 2005;65:620-622. Resumo

33. von Reinhart J. Histamin-intoleranz: histamin und seekrankheit. Stuttgart: Thieme; 2004.

34. Lichtenberg BK, Young LR, Arrott AP. Human ocular counterrolling induced by varying linear accelerations. Exp Brain Res. 1982;48:127-136. Resumo

35. Merfeld DM, Park S, Gianna-Poulin C, et al. Vestibular perception and action employ qualitatively different mechanisms. II. VOR and perceptual responses during combined Tilt&Translation. J Neurophysiol. 2005;94:199-205.Texto completo  Resumo

36. Merfeld DM, Park S, Gianna-Poulin C, et al. Vestibular perception and action employ qualitatively different mechanisms. I. Frequency response of VOR and perceptual responses during Translation and Tilt. J Neurophysiol. 2005;94:186-198.Texto completo  Resumo

37. Wood SJ. Human otolith-ocular reflexes during off-vertical axis rotation: effect of frequency on tilt-translation ambiguity and motion sickness. Neurosci Lett. 2002;323:41-44. Resumo

38. Money KE, Cheung BS. Another function of the inner ear: facilitation of the emetic response to poisons. Aviat Space Environ Med. 1983;54:208-211. Resumo

39. Treisman M. Motion sickness: an evolutionary hypothesis. Science. 1977;197:493-495. Resumo

40. Yates BJ, Miller AD, Lucot JB. Physiological basis and pharmacology of motion sickness: an update. Brain Res Bull. 1998;47:395-406. Resumo

41. Reavley CM, Golding JF, Cherkas LF, et al. Genetic influences on motion sickness susceptibility in adult women: a classical twin study. Aviat Space Environ Med. 2006 Nov;77(11):1148-52.Texto completo  Resumo

42. Drummond PD, Granston A. Facial pain increases nausea and headache during motion sickness in migraineurs. Brain. 2004;127:526-534. Resumo

43. Pavlou M, Lingeswaran A, Davies RA, et al. Simulator based rehabilitation in refractory dizziness. J Neurol. 2004;251:983-95. Resumo

44. Golding JF, Prosyanikova O, Flynn M, et al. The effects of smoking nicotine tobacco versus smoking deprivation on motion sickness. Aviat Space Environ Med. 2008;79:262.

45. Redfern MS, Furman JM, Jacob RG. Visually induced postural sway in anxiety disorders. J Anxiety Disord. 2007;21:704-716.Texto completo  Resumo

46. Redfern MS, Yardley L, Bronstein AM. Visual influences on balance. J Anxiety Disord. 2001;15:81-94. Resumo

47. Romas RT, Jacob RG, Lilienfeld SO. Space and motion discomfort in Brazilian versus American patients with anxiety disorders. J Anxiety Disord. 1997;11:131-139. Resumo

48. Golding JF, Kadzere P, Gresty MA. Motion sickness susceptibility fluctuates through the menstrual cycle. Aviat Space Environ Med. 2005:76; 970-973. Resumo

49. Stern RM, Hu S, Anderson RB, et al. The effects of fixation and restricted visual field on vection-induced motion sickness. Aviat Space Environ Med. 1990;61:712-715. Resumo

50. Streitberger K, Ezzo J, Schneider A. Acupuncture for nausea and vomiting: an update of clinical and experimental studies. Auton Neurosci. 2006;129:107-17. Resumo

51. Hu S, Stern RM, Koch KL. Electrical acustimulation relieves vection-induced motion sickness. Gastroenterology. 1992;102:1854-8. Resumo

52. Denise P, Vouriot A, Normand H, et al. Effect of temporal relationship between respiration and body motion on motion sickness. Auton Neurosci. 2009;151:142-6. Resumo

53. Zhang LL, Wang JQ, Qi RR, et al. Motion sickness: current knowledge and recent advance. CNS Neurosci Ther. 2016 Jan;22(1):15-24.Texto completo  Resumo

54. Golding JF. Predicting individual differences in motion sickness susceptibility by questionnaire. Pers Individ Dif. 2006;41:237-248.

55. Jokerst MD, Gatto M, Fazio R, et al. Slow deep breathing prevents the development of tachygastria and symptoms of motion sickness. Aviat Space Environ Med. 1999;70:1189-1192. Resumo

56. Yen Pik Sang F, Billar JP, Gresty MA, et al. Effect of a novel motion desensitization training regime and controlled breathing on habituation to motion sickness. Percept Mot Skills. 2005;101:244-256. Resumo

57. Yen Pik Sang FD, Billar JP, Golding JF, et al. Behavioral methods of alleviating motion sickness: effectiveness of controlled breathing and a music audiotape. J Travel Med. 2003;10:108-11.Texto completo  Resumo

58. Yen Pik Sang FD, Golding JF, Gresty MA. Suppression of sickness by controlled breathing during mildly nauseogenic motion. Aviat Space Environ Med. 2003;74:998-1002. Resumo

59. Wood CD, Graybiel A. Evaluation of 16 antimotion sickness drugs under controlled laboratory conditions. Aerospace Med. 1968;39:1341-1344.

60. Spinks AB, Wasiak J. Scopolamine (hyoscine) for preventing and treating motion sickness. Cochrane Database Syst Rev. 2011;(6):CD002851.Texto completo  Resumo

61. Burton MJ, Roland PS, Rosenfeld RM. Extracts from The Cochrane Library: Scopolamine (hyoscine) for preventing and treating motion sickness. Otolaryngol Head Neck Surg. 2010;142:468-471. Resumo

62. Stewart JJ, Wood MJ, Parish RC, et al. Prokinetic effects of erythromycin after antimotion sickness drugs. J Clin Pharmacol. 2000;40:347-353. Resumo

63. Bar R, Gil A, Tal D. Safety of double-dose transdermal scopolamine. Pharmacotherapy. 2009;29:1082-1088. Resumo

64. Howland J, Rohsenow DJ, Minsky S, et al. The effects of transdermal scopolamine on simulated ship navigation and attention/reaction time. Int J Occup Environ Health. 2008;14:250-256. Resumo

65. Nachum Z, Shahal B, Shupak A, et al. Scopolamine bioavailability in combined oral and transdermal delivery. J Pharmacol Exp Ther. 2001;296:121-123.Texto completo  Resumo

66. Cowings PS, Toscano WB. Autogenic-feedback training exercise is superior to promethazine for control of motion sickness symptoms. J Clin Pharmacol. 2000;40:1154-65. Resumo

67. Golding JF, Stott JR. Objective and subjective time courses of recovery from motion sickness assessed by repeated motion challenges. J Vestib Res. 1997;7:421-428. Resumo

68. Stern RM, Hu SQ, Vasey MW, et al. Adaptation to vection-induced symptoms of motion sickness. Aviat Space Environ Med. 1989 Jun;60(6):566-72.Texto completo  Resumo

69. Ressiot E, Dolz M, Bonne L, et al. Prospective study on the efficacy of optokinetic training in the treatment of seasickness. Eur Ann Otorhinolaryngol Head Neck Dis. 2013;130:263-268. Resumo

70. Stroud KJ, Harm DL, Klaus DM. Preflight virtual reality training as a countermeasure for space motion sickness and disorientation. Aviat Space Environ Med. 2005;76:352-356. Resumo

71. Dobie TG, May JG. Cognitive-behavioural management of motion sickness. Aviat Space Environ Med. 1994;65:C1-C2. Resumo

72. Toscano WB, Cowings PS. Reducing motion sickness: a comparison of autogenic-feedback training and an alternative cognitive task. Aviat Space Environ Med. 1982;53:449-453. Resumo

73. Javid FA, Naylor RJ. The effect of serotonin and serotonin receptor antagonists on motion sickness in Suncus murinus. Pharmacol Biochem Behav. 2002;73:979-989. Resumo

74. Marcus DA, Furman JM. Prevention of motion sickness with rizatriptan: a double-blind, placebo-controlled pilot study. Med Sci Monit. 2006;12:PI1-PI7. Resumo

75. Furman JM, Marcus DA, Balaban CD. Rizatriptan reduces vestibular-induced motion sickness in migraineurs. J Headache Pain. 2011 Feb;12(1):81-8.Texto completo  Resumo

76. Klocker N, Hanschke W, Toussaint S, et al. Scopolamine nasal spray in motion sickness: a randomised, controlled, and crossover study for the comparison of two scopolamine nasal sprays with oral dimenhydrinate and placebo. Eur J Pharm Sci. 2001;13:227-232. Resumo

77. Ahmed S, Sileno AP, de Meireles JC, et al. Effects of pH and dose on nasal absorption of scopolamine hydrobromide in human subjects. Pharm Res. 2000;17:974-977. Resumo

78. Simmons RG, Phillips JB, Lojewski RA, et al. The efficacy of low-dose intranasal scopolamine for motion sickness. Aviat Space Environ Med. 2010;81:405-412. Resumo

79. Stankovic AS, Alvarenga DL, Coleman Daniels VR, et al. Intranasal scopolamine for motion sickness. Aerosp Med Hum Perform. 2019 Nov 1;90(11):917-24.Texto completo  Resumo

80. Grunfeld E, Price C, Goadsby P, et al. Migraine, motion sickness and menstruation in mariners. Lancet. 1998;351:1106. Resumo

O uso deste conteúdo está sujeito ao nosso aviso legal